Cardiovascular Disease (CVD) Phenotyping Core

心血管疾病 (CVD) 表型核心

• 批准号: 10333815
• 负责人: ARSHED A QUYYUMI
• 金额: $ 41.13万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-15 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10333815
• 关键词: Autopsy; Biochemical; Biological Markers; Blood; Blood Vessels; Cardiac; Cardiovascular Diseases; Cardiovascular system; Cessation of life; Clinical; Clinics and Hospitals; Collection; Consent; Coronary; Coronary Arteriosclerosis; Data; Data Analyses; Data Collection; Databases; Death Certificates; Diagnosis; Disease Outcome; Documentation; Elements; Enrollment; Equipment; Event; Fatty Liver; Fatty acid glycerol esters; Foundations; Functional disorder; Goals; Health; Health Care Visit; Heart failure; Hepatic; Household; India; Inflammation; Infrastructure; Institution; International; Interviewer; Laboratories; Lead; Left; Link; Lipids; Logistics; Measurement; Measures; Metabolic; Monitor; Myocardial; Myocardial Infarction; Myocardial dysfunction; Participant; Pathway interactions; Peripheral arterial disease; Persons; Phenotype; Physiologic pulse; Play; Process; Program Research Project Grants; Proteins; Protocols documentation; Quality Control; Questionnaires; Reading; Reproducibility; Research; Risk Factors; Role; Sampling; Services; Specimen; Standardization; Stress; Stroke; Structure; Symptoms; Techniques; Testing; Time; Training; Transient Ischemic Attack; Transportation; Urine; Vascular Diseases; Ventricular; Visit; Work; adipokines; adjudication; arterial stiffness; base; cardiovascular imaging; carotid intima-media thickness; clinical phenotype; cohort; coronary artery calcium; coronary calcium scoring; data acquisition; data management; disease phenotype; experience; immune activation; indexing; mortality; novel; phenotypic data; quality assurance; sample collection; secondary outcome; success; synergism; thrombogenesis

PROJECT SUMMARY / ABSTRACT: Cardiovascular Disease (CVD) Phenotyping Core The Cardiovascular Disease (CVD) Phenotyping Core will be responsible for advanced subclinical and clinical CVD phenotyping of all participants enrolled in the Precision Cardiovascular Phenotyping and Pathophysiological Pathways in the CARRS cohort (Precision-CARRS) program project grant (PPG). Responsibilities include providing coordination, expertise, and standardization of all elements related to the proposed phenotyping. The overarching goal of the Core is to obtain the highest quality of CVD subclinical and clinical phenotyping in this cohort and further train existing teams and standardize protocols for (a) novel advanced CVD phenotyping in the field, (b) cardiovascular imaging in central facilities, (c) centralized interpretation of all tests, (d) adjudication of subclinical and clinical CVD events and mortality, (e) blood and urine testing and laboratory services, together with quality assurance and quality control. The CVD Phenotyping Core will be based in Delhi, India and will consolidate and augment existing infrastructure and expertise and leverage a decade of collaborative experience between Emory and India’s leading health research institutions. Specific Aim 1 is to formulate and implement plans for accurate and reproducible phenotyping of sub-clinical CVD that includes measures of (i) functional vascular disease assessed as pulse wave velocity and augmentation index that reflect arterial stiffness; (ii) coronary artery calcium, a reflection of subclinical coronary atherosclerosis; (iii) carotid intima-media thickness and plaque; (iv) hepatic steatosis; and (v) sub-clinical myocardial dysfunction measured as left ventricular systolic or diastolic dysfunction using cardiac echo. Aim 2 will implement plans to standardize adjudication of prevalent and incident clinical CVD events to include atherosclerotic events and occurrence of heart failure. Atherosclerotic events will include incident cardiovascular death, myocardial infarction, and stroke or transient ischemic attacks. Secondary outcomes include diagnosis of angina or coronary or peripheral arterial disease, and revascularization. Heart failure occurrences will include diagnosis of symptomatic Stage C or D heart failure. In Aim 3, we will formulate and implement laboratory sample collection and analysis for all biomarkers analyses, to include traditional risk factors, advanced lipid and metabolic measures, and circulating proteins that reflect activation of pathophysiologic processes associated with CVD. The Core will work in close coordination with the Administrative and Field Coordination Core which will administer the field logistics. Acquired data will be transferred to the Data Management and Analysis Core, and provide curated CVD phenotyping data to all 4 PPG projects.

项目总结/摘要：心血管疾病（CVD）表型核心 心血管疾病（CVD）表型核心将负责晚期亚临床和 入组精密心血管表型分析的所有受试者的临床CVD表型分析， CARRS队列（Precision-CARRS）计划项目资助（PPG）中的病理生理学途径。 职责包括提供协调，专业知识，和标准化的所有要素相关的 提出的表型。核心的首要目标是获得最高质量的心血管亚临床和 在该队列中进行临床表型分析，并进一步培训现有团队并标准化（a）新的 先进的CVD表型在外地，（B）心血管成像在中央设施，（c）集中 所有测试的解释，（d）亚临床和临床CVD事件和死亡率的裁定，（e）血液和 尿液测试和化验服务，以及质量保证和质量控制。的CVD Phenotyping Core将设在印度德里，并将巩固和扩大现有的基础设施， 专业知识，并利用埃默里大学和印度领先的健康 研究机构具体目标1是制定和实施计划， 亚临床CVD的表型分析，包括（i）评估为脉搏的功能性血管疾病 反映动脉硬度的波速度和增强指数;（ii）冠状动脉钙，反映 亚临床冠状动脉粥样硬化;（iii）颈动脉内膜中层厚度和斑块;（iv）肝脂肪变性;和 (v)亚临床心肌功能障碍，测量为左心室收缩或舒张功能障碍，使用 心脏回波目标2将实施计划，以标准化流行和偶发临床CVD的裁定 事件包括动脉粥样硬化事件和心力衰竭的发生。体育赛事将包括 意外心血管死亡、心肌梗死和中风或短暂性脑缺血发作。二次 结果包括心绞痛或冠状动脉或外周动脉疾病的诊断以及血管重建。心脏 衰竭发生将包括诊断为症状性C或D期心力衰竭。在目标3中，我们将制定 并实施实验室样本收集和分析，用于所有生物标志物分析，包括传统的风险 因子，高级脂质和代谢指标，以及反映活化的循环蛋白质。 与CVD相关的病理生理过程。核心小组将与联合国秘书长密切协调， 行政和外地协调核心，负责管理外地后勤。获取的数据将 转移到数据管理和分析核心，并提供策划的CVD表型数据，以所有4 PPG项目。